Radius Health, Inc.

- Formation Bio appointed four senior executives including Louis Brenner, MD as Chief Medical Officer and Daniel Neil, PhD as Chief Technology Officer to strengthen its AI-native pharmaceutical model. - Former Pfizer CFO Frank D'Amelio and ex-Incyte CSO Dashyant Dhanak, PhD joined as Strategic Advisors to guide the company's drug licensing and acquisition decisions. - The leadership expansion supports Formation Bio's plan to grow its pipeline from current assets to 10-15 drug candidates over the next 3-5 years. - The company recently secured a €545M out-licensing deal and added a new autoimmune disease asset to its development portfolio.

Sep 18, 2025

Back to Organizations

Radius Health, Inc.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (33)

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Elacestrant Monotherapy for the Treatment of ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, OpenLabel, Active-Controlled, Multicenter Trial

A study to see the Safety and Efficacy of Abaloparatide- SC for the Treatment of Men with Osteoporosis

Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.

Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.

BA058 Transdermal Phase 3 Study in Women with Osteoporosis

BA058 Transdermal Phase 3 Study in Women with Osteoporosis

BA058 Transdermal Phase 3 Study in Women with Osteoporosis

Approvals

Approvals by Agency

Recent Approvals

News

Formation Bio Strengthens Leadership Team with Former Pfizer and BenevolentAI Executives to Advance AI-Driven Drug Development